Target Audience and Goal Statement
This educational activity is intended for an international audience of non-US healthcare professionals, specifically psychiatrists,
primary care physicians, and neurologists involved in the management of patients with major depressive disorder (MDD).
The goal of this activity is to increase knowledge of the symptoms, diagnosis and treatment of patients with cognitive impairment
and MDD in the specialist and primary care setting using a case-based discussion.
Upon completion of this activity, participants will be able to:
- Identify approaches to the successful treatment of cognitive dysfunction in patients with MDD
- Recognize comorbidities and key aspects of patient history that lead to the diagnosis of cognitive dysfunction in MDD
- Describe the effect of cognitive impairment on the patient's daily living and the effect of a correct diagnosis on patient
outcomes
Disclosures
WebMD Global requires each individual who is in a position to control the content of one of its educational activities to
disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.
Moderator
-
Koen Demyttenaere, MD, PhD
Academic Chair, University Psychiatric Center; Professor of Psychiatry, Faculty of Medicine, Katholieke Universiteit Leuven,
Leuven, Belgium; Co-holder, Fortune Fund Chair (Ga voor Geluk), Belgium
Disclosures
Disclosure: Koen Demyttenaere, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; Lundbeck, Inc.; SERVIER
Served as a speaker or a member of a speakers bureau for: Eli Lilly and Company; Lundbeck, Inc.; SERVIER
Received grants for clinical research from: Eli Lilly and Company; Lundbeck, Inc.; SERVIER
Panelists
-
Bernhard Baune, MD, PhD
Professor and Chair of Psychiatry; Head, Discipline of Psychiatry, School of Medicine, Royal Adelaide Hospital, University
of Adelaide, Adelaide, Australia
Disclosures
Disclosure: Bernhard Baune, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Lundbeck, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Lundbeck,
Inc.; Pfizer Inc.; SERVIER; Wyeth Pharmaceuticals Inc.
Received grants for clinical research from: National Health and Medical Research Council, Australia
-
Eduard Vieta, MD, PhD
Chair, Department of Psychiatry and Psychology, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain
Disclosures
Disclosure: Eduard Vieta, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Almirall Hermal GmbH; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company;
Dainippon Sumitomo Pharma America; Eli Lilly and Company; Esteve; Ferrer; Forest Laboratories, Inc.; GlaxoSmithKline; Janssen
Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation;
Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Pierre Fabre; Richter Pharma AG; Roche; Sanofi; SERVIER; Shire; Solvay Pharmaceuticals,
Inc.; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.; UCB Pharma, Inc.
Received grants for clinical research from: Almirall Hermal GmbH; Bristol-Myers Squibb Company; GlaxoSmithKline; European
7th Framework Program: Janssen-Cilag; NARSAD; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co., Ltd.; Pfizer
Inc.; Richter Pharma AG; Roche; Sanofi; Seny Foundation; SERVIER; Spanish Ministry of Health (CIBERSAM); Spanish Ministry
of Science and Education; Stanley Medical Research Institute; Teva Pharmaceutical Industries Ltd.
Steering Committee
-
Guy M. Goodwin, FMedSci
Professor of Psychiatry, Department of Psychiatry, University of Oxford, Oxford, United Kingdom
Disclosures
Disclosure: Guy M. Goodwin, FMedSci, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Otsuka Pharmaceutical Co., Ltd.; SERVIER;
Sunovion Pharmaceuticals Inc.; Teva Neuroscience, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; GlaxoSmithKline;
Lundbeck, Inc.; Otsuka Pharmaceutical Co., Ltd.; SERVIER
Received grants for clinical research from: SERVIER
Owns stock, stock options, or bonds from: P1vital
-
John Harrison, CSci, CPsychol
Associate Professor, Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands
Disclosures
Disclosure: John Harrison, CSci, CPsychol, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Anavex Life Sciences Corp.; AstraZeneca Pharmaceuticals LP;
Avraham Pharmaceuticals; AXON; Biogen Idec Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bracket Global; Catenion; CRF
Health; Dendron UK; Eisai Co., Ltd; Eli Lilly and Company; EnVivo Pharmaceuticals; Enzymotec Ltd.; ePharmaSolutions; Heptares;
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Kyowa Hakko Kirin Co., Ltd.; Lundbeck, Inc.; MedAvante; Mind
Agilis; MyCognition; Neurocog; Novartis Pharmaceuticals Corporation; Nutricia; Orion Corporation; Pfizer Inc.; Prana Biotechnology;
Pricespective; ProPhase; ProStrakan, Inc.; Reviva Pharmaceuticals Inc.; Roche; SERVIER; Shire; Takeda Pharmaceuticals North
America, Inc.; TCG; TransTech Pharma; UCB Pharma, Inc.; Velacor
Served as a speaker or a member of a speakers bureau for: Lundbeck, Inc.
Owns stock, stock options, or bonds from: Neurotrack
Employed by a commercial interest: Metis Cognition Ltd
Other: Received royalties from Oxford University Press & Blackwell Publishers
-
Siegfried Kasper, MD
Professor and Chair, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
Disclosures
Disclosure: Siegfried Kasper, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Angelini; Bristol-Myers Squibb Company; Eli Lilly and Company GlaxoSmithKline; Janssen
Pharmaceuticals; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Organon International Inc.; Pfizer Inc.; Pierre Fabre; Schwabe
Pharmaceuticals; Sepracor Inc.; SERVIER; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: Angelini; AOP Orphan Pharmaceuticals AG; AstraZeneca Pharmaceuticals
LP; Bristol-Myers Squibb Company; GlaxoSmithKline; Janssen Pharmaceuticals; Lundbeck, Inc.; Merck Sharp & Dohme Corp.; Organon
International Inc.; Pierre Fabre; Schwabe Pharmaceuticals; SERVIER; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Lundbeck, Inc.
-
Raymond W. Lam, MD, FRCPC
Professor and Associate Head for Research, Department of Psychiatry, University of British Columbia; Director, Mood Disorders
Centre, UBC Hospital, Vancouver Coastal Health; Executive Chair, Canadian Network for Mood and Anxiety Treatments (CANMAT),
Vancouver, British Columbia, Canada
Disclosures
Disclosure: Raymond W. Lam, MD, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Eli Lilly and Company; Johnson & Johnson Pharmaceutical
Research & Development, L.L.C.; Lundbeck, Inc.; Mochida; Pfizer Inc.; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Lundbeck, Inc.; Otsuka Pharmaceutical
Co., Ltd.; SERVIER
Received grants for clinical research from: Bristol-Myers Squibb Company; Lundbeck, Inc.; Pfizer Inc.; St. Jude MedicalOther: Received book royalties from Cambridge University Press, Oxford University Press, Informa Press
-
Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology, University of Toronto; Head of the Mood Disorders Psychopharmacology Unit, University
Health Network, Toronto, Ontario, Canada
Disclosures
Disclosure: Roger S. McIntyre, MD, FRCPC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Eli Lilly and Company;
GlaxoSmithKline; Janssen-Ortho Inc.; Lundbeck, Inc.; Merck & Co., Inc.; Organon Pharmaceuticals USA Inc.; Pfizer Inc.; Shire
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen-Ortho
Inc.; Lundbeck, Inc.; Merck & Co., Inc.; Pfizer Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; Janssen-Ortho Inc.; Lundbeck,
Inc.; Pfizer Inc.; Shire
-
David J. Nutt, MD, PhD
Edmond J. Safra Professor of Neuropsychopharmacology; Head of the Centre for Neuropsychopharmacology, Imperial College London,
London, United Kingdom
Disclosures
Disclosure: David J. Nutt, MD, PhD,has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; Lundbeck, Inc.; Merck Sharp & Dohme Corp.
Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline;
Janssen Pharmaceuticals, Inc.; NalPharm; Otsuka Pharmaceutical Co., Ltd.
Received grants for clinical research from: GlaxoSmithKline; Lundbeck, Inc.
Owns stock, stock options, or bonds from: P1vital
Other: Received writing fees: Reckitt Benckiser For each editor, include the following:
Editor
Content Reviewer
Accreditation Statements
For questions regarding the content of this activity, contact the
accredited provider for this CME/CE activity noted above. For technical
assistance, contact [email protected]
Instructions for Participation and Credit
There are no fees for participating in or receiving credit for this online educational activity. For information about your
eligibility to claim credit, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must
complete the activity online during the credit eligibility period that is noted on the title page.
Follow these steps to claim a credit certificate for completing this activity:
- Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures,
read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test
and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this
activity, we will issue you a CPD credit certificate.
- Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits
will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the
tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.
We encourage you to complete an Activity Evaluation to provide feedback for future programming.
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
